Efficacy of JZL184 treatment to reduce AD hallmarks in 5xFAD mice has been previously described 11, and we employed a similar paradigm with JZL184 treatment to assess [18F]MAGL-2102 PET after MAGL inhibition. This evidence concerns the gene MGLL and Alzheimer disease.